The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Nilotinib in Imatinib-Resistant CML and Philadelphia Chromosome–Positive ALL
Open accessAbstract
BACKGROUND: Resistance to imatinib mesylate can occur in chronic myelogenous leukemia (CML). Preclinical in vitro studies have shown that nilotinib (AMN107), a new BCR-ABL tyrosine kinase inhibitor, is more potent than imatinib against CML cells by a factor of 20 to 50. METHODS: In a phase 1 dose-escalation study, we assigned 119 patients with imatinib-resistant CML or acute lymphoblastic leukemia (ALL) to receive nilotinib orally at doses of 50 mg, 100 mg, 200 mg, 400 mg, 600 mg, 800 mg, and 1200 mg once daily and at 400 mg and 600 mg twice daily. RESULTS: Common adverse events were myelosuppression, transient indirect hyperbilirubinemia, and rashes. Of 33 patients with the blastic phase of disease, 13 had a hematologic response and 9 had a cytogenetic response; of 46 patients with the accelerated phase, 33 had a hematologic response and 22 had a cytogenetic response; 11 of 12 patients with the chronic phase had a complete hematologic remission. CONCLUSIONS: Nilotinib has a relatively favorable safety profile and is active in imatinib-resistant CML. (ClinicalTrials.gov number, NCT00109707 [ClinicalTrials.gov].).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
O'Brien, S. G., Guilhot, F., Larson, R. A., Gathmann, I., Baccarani, M., Cervantes, F., Cornelissen, J. J., Fischer, T., Hochhaus, A., Hughes, T., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022457 · Cited by 3,570
Self-citationHematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous Leukemia
Kantarjian, H., Sawyers, C., Hochhaus, A., Guilhot, F., Schiffer, C., Gambacorti-Passerini, C., Niederwieser, D., Resta, D., Capdeville, R., Zoellner, U., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011573 · Cited by 2,019
Self-citationDasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias
Talpaz, M., Shah, N. P., Kantarjian, H., Donato, N., Nicoll, J., Paquette, R., Cortes, J., O'Brien, S., Nicaise, C., Bleickardt, E., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055229 · Cited by 1,760
Self-citationBosma, P. J., Chowdhury, J. R., Bakker, C., Gantla, S., de Boer, A., Oostra, B. A., Lindhout, D., Tytgat, G. N. J., Jansen, P. L. M., Elferink, R. P. J. O., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511023331802 · Cited by 1,447
O'Hare, T., Walters, D. K., Stoffregen, E. P., Jia, T., Manley, P. W., Mestan, J., Cowan-Jacob, S. W., Lee, F. Y., Heinrich, M. C., Deininger, M. W. N., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0259 · Cited by 1,036
Self-citationThomas, D. A. (2004) · Blood · doi:10.1182/blood-2003-08-2958 · Cited by 571
Ottmann, O. G. (2002) · Blood · doi:10.1182/blood-2001-12-0181 · Cited by 555
Self-citationChronic Myelogenous Leukemia: Biology and Therapy
Faderl, S., Talpaz, M., Estrov, Z., & Kantarjian, H. M. (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-131-3-199908030-00008 · Cited by 462
Self-citationPractical Management of Patients With Chronic Myeloid Leukemia Receiving Imatinib
Deininger, M. W. N., O’Brien, S. G., Ford, J. M., & Druker, B. J. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.11.143 · Cited by 402
Self-citationKantarjian, H., Talpaz, M., O'Brien, S., Garcia-Manero, G., Verstovsek, S., Giles, F., Rios, M. B., Shan, J., Letvak, L., Thomas, D., et al. (2004) · Blood · doi:10.1182/blood-2003-11-3800 · Cited by 392
Self-citationKantarjian, H. M., Cortes, J., O'Brien, S., Giles, F. J., Albitar, M., Rios, M. B., Shan, J., Faderl, S., Garcia-Manero, G., Thomas, D. A., et al. (2002) · Blood · doi:10.1182/blood.v99.10.3547 · Cited by 295
Self-citationCohen, M. H., Johnson, J. R., & Pazdur, R. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0722 · Cited by 282
Chronic myelogenous leukemia in blast crisis
Kantarjian, H. M., Keating, M. J., Talpaz, M., Walters, R. S., Smith, T. L., Cork, A., McCredie, K. B., & Freireich, E. J. (1987) · The American Journal of Medicine · doi:10.1016/0002-9343(87)90754-6 · Cited by 277
Self-citationCharacteristics of accelerated disease in chronic myelogenous leukemia
Kantarjian, H. M., Dixon, D., Keating, M. J., Talpaz, M., Walters, R. S., McCredie, K. B., & Freireich, E. J. (1988) · Cancer · doi:10.1002/1097-0142(19880401)61:7<1441::aid-cncr2820610727>3.0.co;2-c · Cited by 270
Self-citationCortes, J. E., Talpaz, M., O'Brien, S. M., Jones, D. M., Luthra, R., Shan, J., Giles, F. J., Faderl, S. H., Verstovšek, S., Garcia‐Manero, G., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2139 · Cited by 264
Self-citationCortes, J. E., Talpaz, M., Giles, F., O'Brien, S., Rios, M. B., Shan, J., Garcia-Manero, G., Faderl, S., Thomas, D. A., Wierda, W., et al. (2003) · Blood · doi:10.1182/blood-2002-09-2790 · Cited by 236
Self-citationGolemovic, M., Verstovsek, S., Giles, F., Cortes, J., Manshouri, T., Manley, P. W., Mestan, J., Dugan, M., Alland, L., Griffin, J. D., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2601 · Cited by 203
Self-citationDeletion of the alternatively spliced fibronectin EIIIA domain in mice reduces atherosclerosis
Tan, M. H., Sun, Z., Opitz, S. L., Schmidt, T. E., Peters, J. H., & George, E. L. (2004) · Blood · doi:10.1182/blood-2003-09-3363 · Cited by 178
Verstovšek, S., Golemović, M., Kantarjian, H. M., Manshouri, T., Estrov, Z. E., Manley, P. W., Sun, T., Arlinghaus, R. B., Alland, L., Dugan, M. H., et al. (2005) · Cancer · doi:10.1002/cncr.21299 · Cited by 77
Self-citation
Cited by
Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia
Druker, B. J., Guilhot, F., O'Brien, S. G., Gathmann, I., Kantarjian, H., Gattermann, N., Deininger, M. W. N., Silver, R. T., Goldman, J. M., Stone, R. M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062867 · Cited by 3,488
Self-citationDasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias
Talpaz, M., Shah, N. P., Kantarjian, H., Donato, N., Nicoll, J., Paquette, R., Cortes, J., O'Brien, S., Nicaise, C., Bleickardt, E., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055229 · Cited by 1,760
Self-citationPui, C.-H., Robison, L. L., & Look, A. T. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60457-2 · Cited by 1,564
Baccarani, M., Cortes, J., Pane, F., Niederwieser, D., Saglio, G., Apperley, J., Cervantes, F., Deininger, M., Gratwohl, A., Guilhot, F., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.0779 · Cited by 1,291
Self-citationCardiovascular Complications of Cancer Therapy
Yeh, E. T. H., & Bickford, C. L. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.02.050 · Cited by 1,275
Metadata
- Authors
- Kantarjian, H., Giles, F., Wunderle, L., Bhalla, K., O'Brien, S., Wassmann, B., Tanaka, C., Manley, P., Rae, P., Mietlowski, W., Bochinski, K., Hochhaus, A., Griffin, J. D., Hoelzer, D., Albitar, M., Dugan, M., Cortes, J., Alland, L., & Ottmann, O. G.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2006-06-15
- Volume
- 354
- Issue
- 24
- Pages
- 2542-2551
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2054251966
- Cited by
- 1,344
- References
- 20
- FWCI
- 77.98
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.